4CPS-119 Effectiveness of capecitabine treatment in metastasic colorectal cancer in elderly patients

Background Age is the major risk factor for metastasic colorectal cancer (mCRC), with 70% of patients older than 70 years. Furthermore, elderly patients are not represented enough in cancer clinical trials, so there is a lack of information about these patients. Purpose To analyse the effectiveness of capecitabine treatment in mCRC in elderly patients. Material and methods A descriptive, observational and retrospective study performed in a tertiary hospital. We included all patients over 65 diagnosed with mCRC in treatment with capecitabine during 2014 and 2015. The variables analysed were: age, sex, line and treatment strategy, treatment duration, progression-free survival (PFS) and overall survival (OS). Statistical analysis was performed stratifying patients according to treatment in monotherapy or combined and first or later lines using the SPSS ® package. Results A total of 34 patients with a mean age at baseline of 75±6.2 years (76.5% were males) were included. Twenty-four patients (70.6%) were treated with monotherapy and 20 (71.3%) in the first line of treatment. The median duration of treatment was 16 weeks, 20 weeks in monotherapy versus 11 in combined treatment and 20 weeks in the first line of treatment versus 14 in successive lines. PFS was 16.8 weeks in monotherapy versus 9 weeks in combination (log-rank: p=0.3, Breslow: p=0.138) and 16.7 weeks in the first line versus 11.4 weeks in later lines (log-rank: p=0.785; Breslow: p=0493). OS was 13.4 months in monotherapy versus 11.4 months in combination (log-rank: p=0.606, Breslow: p=0.756) and 20.1 months in the first line versus 10.4 months in successive lines (log-rank: p=0,159, Breslow: p=0.248). Conclusion Monotherapy and the first line of treatment were of the longest duration. PFS and OS were superior in treatment alone and in the first line of treatment. These differences were clinically relevant although there were no statistically significant differences. No conflict of interest